Xeris Biopharma Holdings, Inc. XERS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s operating cash flow?
- Xeris Biopharma Holdings, Inc. (XERS) reported operating cash flow of $9.87M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s operating cash flow changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s operating cash flow increased by 198.4% year-over-year, from -$10.03M to $9.87M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s operating cash flow?
- Over 3 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s operating cash flow has grown at a -33.1% compound annual growth rate (CAGR), from -$95.54M to $28.63M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.